C4 Therapeutics, Inc. (CCCC) stock
CCCCNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 5, 2026Score 8/3019% above fair value
$2.77−0.12 (-4.15%)
Close on Nov 12, 2026Market cap $340.78MP/E –Yield –
C4 Therapeutics ebitda
EBITDA is earnings before interest, taxes, depreciation and amortization, a rough measure of cash profit from operations.
C4 Therapeutics's ebitda for the twelve months ending Sep 30, 2026 was -$100.51M. For fiscal 2025 it was -$113.26M. The highest annual figure on record is -$33.86M in fiscal 2019.
Annual ebitda
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$113.26M | – |
| FY2024 | Dec 31, 2024 | -$117.80M | – |
| FY2023 | Dec 31, 2023 | -$137.15M | – |
| FY2022 | Dec 31, 2022 | -$127.86M | – |
| FY2021 | Dec 31, 2021 | -$80.64M | – |
| FY2020 | Dec 31, 2020 | -$58.83M | – |
| FY2019 | Dec 31, 2019 | -$33.86M | – |
Quarterly ebitda
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | -$24.28M | – |
| Q2 FY2026 | Jun 30, 2026 | -$26.13M | – |
| Q1 FY2026 | Mar 31, 2026 | -$27.38M | – |
| Q4 FY2025 | Dec 31, 2025 | -$22.72M | – |
| Q3 FY2025 | Sep 30, 2025 | -$33.95M | – |
| Q2 FY2025 | Jun 30, 2025 | -$27.89M | – |
| Q1 FY2025 | Mar 31, 2025 | -$28.71M | – |
| Q4 FY2024 | Dec 31, 2024 | -$37.23M | – |
| Q3 FY2024 | Sep 30, 2024 | -$27.80M | – |
| Q2 FY2024 | Jun 30, 2024 | -$20.99M | – |
| Q1 FY2024 | Mar 31, 2024 | -$31.77M | – |
| Q4 FY2023 | Dec 31, 2023 | -$37.00M | – |
| Q3 FY2023 | Sep 30, 2023 | -$27.36M | – |
| Q4 FY2020 | Dec 31, 2020 | -$18.54M | – |
| Q4 FY2019 | Dec 31, 2019 | -$10.08M | – |
See a number that looks wrong?